Kaposi Sarcoma – Pipeline Review, 2024

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1.Report Overview

2. Kaposi Sarcoma - Overview

3. Executive Summary

4. Kaposi Sarcoma : PipelineAssessment

4.1.By Stage of Development

4.2.By Route of Administration

4.3.By Drug Class

4.4.By Molecule Type

4.5.By Therapy Area / Indication

4.6.By Drug Target

4.7.By Sponsor

5. Kaposi Sarcoma: Company & DrugProfiles

5.1.Clinical Stage

5.1.1. Pomalidomide– National CancerInstitute (NCI)

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status &Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. Bortezomib – National CancerInstitute (NCI)

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status &Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. imatinib mesylate – AIDSMalignancy Consortium

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status &Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2.Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status &Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Kaposi Sarcoma: An Overview onDormant & Discontinued Pipeline Candidates

6.1.Overview

6.2.Product Description

6.3.Reason for Discontinuation

7. Kaposi Sarcoma: Additional KeyInsights

7.1.Epidemiology Overview: Kaposi Sarcoma

7.2.Current Market Scenario: Kaposi Sarcoma Therapeutics

8. Kaposi Sarcoma: News, PressReleases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.